New Frontiers in Biopharmaceuticals: Safety and Pharmacokinetic Challenges
*Corresponding Author: Anoja Priyadarshani, Department of Pathology, Faculty of Medicine, University of Ruhuna, Sri Lanka, Email: anojapriyadarshani@23gmail.comReceived Date: Jul 02, 2024 / Published Date: Jul 30, 2024
Citation: Anoja P (2024) New Frontiers in Biopharmaceuticals: Safety andPharmacokinetic Challenges. World J Pharmacol Toxicol 7: 260.
Copyright: © 2024 Anoja P. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Abstract
The advancement of biopharmaceuticals has ushered in a new era of targeted therapies for various complex diseases. However, the unique properties of these therapies present distinct challenges related to safety and pharmacokinetics. This article explores the primary safety concerns associated with biopharmaceuticals, including immunogenicity, infusion-related reactions, and long-term safety. It also examines pharmacokinetic challenges such as the complexity of drug behavior, dosing and administration issues, and biodistribution limitations. Innovative strategies to address these challenges, such as protein engineering, advanced drug delivery systems, personalized medicine, and real-world evidence, are discussed. Understanding and overcoming these challenges is crucial for optimizing the efficacy and safety of biopharmaceutical treatments, ultimately improving patient outcomes
